(MENAFN- Saudi Press Agency) SILVER SPRING Md. U.S.A. Muharram 25 1437 November 07 2015 SPA -- The U.S. Food and Drug Administration announced today its approval of a new all-in-one pill to treat HIV patients that includes a new version of the drug tenofovir which researchers think will help reduce side effects from the multi-drug regimens used for HIV UPI reported.
The pill called Genvoya includes doses of elvitegravir cobicistat emtricitabine and tenofovir alafenamide and is meant especially for patients over age 12 who weigh at least 77 pounds and have not previously been treated for HIV.
In addition to reducing side effects the drug also was associated with less kidney toxicity and fewer reductions in bone density credited to other drugs that contain tenofovir. Patients who already have significant kidney problems however should not be treated with the drug the agency said.
Gilead Sciences the California-based company that developed Genvoya conducted four clinical trials with 3171 participants who were randomly assigned to receive either the new pill or another HIV treatment. The testing was conducted in 21 countries with a wide variety of patients including treatment-naive virologically suppressed renally impaired and adolescent patients.
--SPA
02:34 LOCAL TIME 23:34 GMT
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.